Compare GLBS & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLBS | PLUR |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | Greece | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.0M | 28.4M |
| IPO Year | 2007 | N/A |
| Metric | GLBS | PLUR |
|---|---|---|
| Price | $1.75 | $3.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 94.0K | 26.6K |
| Earning Date | 11-28-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,444,000.00 | $1,326,000.00 |
| Revenue This Year | $24.03 | $97.38 |
| Revenue Next Year | $13.92 | $293.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.49 | ★ 121.74 |
| 52 Week Low | $0.99 | $2.82 |
| 52 Week High | $1.99 | $7.13 |
| Indicator | GLBS | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 59.33 | N/A |
| Support Level | $1.62 | N/A |
| Resistance Level | $1.82 | N/A |
| Average True Range (ATR) | 0.08 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 55.00 | 0.00 |
Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.